<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prasugrel: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prasugrel: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prasugrel: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12218" href="/d/html/12218.html" rel="external">see "Prasugrel: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F11238845"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prasugrel can cause significant, sometimes fatal, bleeding. Do not use prasugrel in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke.</p>
<p style="text-indent:-2em;margin-left:2em;">In patients ≥75 years, prasugrel is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of myocardial infarction [MI]) in which its effect appears to be greater and its use may be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not start prasugrel in patients likely to undergo urgent coronary artery bypass graft (CABG) surgery. When possible, discontinue prasugrel at least 7 days prior to any surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional risk factors for bleeding include body weight &lt;60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, long-term use of nonsteroidal anti-inflammatory drugs [NSAIDs]).</p>
<p style="text-indent:-2em;margin-left:2em;">Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of prasugrel.</p>
<p style="text-indent:-2em;margin-left:2em;">If possible, manage bleeding without discontinuing prasugrel. Discontinuing prasugrel, particularly in the first few weeks after acute coronary syndrome (ACS), increases the risk of subsequent cardiovascular events.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7901908"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Effient</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870779"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Effient [DSC];</li>
<li>JAMP Prasugrel</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F7910294"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent;</li>
<li>
                        Antiplatelet Agent, Thienopyridine;</li>
<li>
                        P2Y12 Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F7912224"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Safety: </b>Avoid use in patients with active bleeding or a history of stroke or transient ischemic attack. In patients who require concomitant therapeutic anticoagulation, antiplatelet selection and/or duration of therapy may differ in order to balance risks for thrombosis and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86b6fd8e-962b-456c-a545-7cc4fac97799">Acute coronary syndrome managed by percutaneous coronary intervention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome (non-ST-elevation myocardial infarction, unstable angina, or ST-elevation myocardial infarction) managed by percutaneous coronary intervention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For ST-elevation myocardial infarction managed with primary percutaneous coronary intervention (PCI), administer as early as possible after diagnosis. For non-ST-elevation acute coronary syndromes, administer after angiography once clinician decides to perform PCI; if PCI is not performed, use an alternative P2Y<sub>12</sub> inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-23991622','lexi-content-ref-17982182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-23991622','lexi-content-ref-17982182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i>
<b>Oral:</b> 60 mg once before PCI in combination with aspirin and a parenteral anticoagulant; followed by maintenance dosing. If coronary angiography is planned soon after diagnosis, it is reasonable to delay the initial loading dose until after coronary anatomy is known (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> ≥60 kg: 10 mg once daily in combination with aspirin beginning the day after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-17982182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-17982182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>East Asian descent:</i> After 30 days, consider reducing to 5 mg once daily in patients of East Asian descent in order to decrease bleeding risk. <b>Note:</b> Patients of East Asian descent display a greater antiplatelet response compared to white patients. A reduced dose of prasugrel (5 mg once daily) after 30 days had a similar reduction in thrombotic events and fewer bleeding events compared to continuation of a higher maintenance dose (10 mg once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32882163','lexi-content-ref-25154978','lexi-content-ref-19888568']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32882163','lexi-content-ref-25154978','lexi-content-ref-19888568'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> &lt;60 kg: 5 mg once daily in combination with aspirin beginning the day after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23083774','lexi-content-ref-32687741','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23083774','lexi-content-ref-32687741','lexi-content-ref-Manu.1'])">Ref</a></span>). An alternative P2Y<sub>12</sub> inhibitor may be considered if bleeding is major concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Preferred approach: Continue prasugrel plus aspirin (dual antiplatelet therapy [DAPT]) for ≥12 months unless major bleeding is a concern. For patients at high risk of bleeding or who experience overt bleeding, DAPT for 6 months may be reasonable. If there have been no major bleeding complications after 12 months, continuation of DAPT may be considered. Reevaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue prasugrel and continue aspirin indefinitely for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-25399658','lexi-content-ref-17982182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-25399658','lexi-content-ref-17982182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative approach in select patients to minimize bleeding events: Prasugrel in combination with aspirin (DAPT) should be continued for 1 to 3 months after PCI, then discontinue aspirin and continue prasugrel monotherapy. When prasugrel is discontinued, restart aspirin for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-32551860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-32551860'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning between P2Y<sub>12</sub> inhibitors: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: This provides general guidance on transitioning between P2Y<sub>12</sub> inhibitors.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning from another P2Y<sub>12 </sub>inhibitor to prasugrel:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Transitioning from clopidogrel:</i></p>
<p style="text-indent:-2em;margin-left:10em;">≤30 days after acute coronary syndrome (ACS) or PCI: Give prasugrel 60 mg loading dose once (irrespective of timing of previous clopidogrel dose), followed the next day by 10 mg once daily (≥60 kg) or 5 mg once daily (&lt;60 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-20846599','lexi-content-ref-18569863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-20846599','lexi-content-ref-18569863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;30 days after ACS or PCI: Give prasugrel 10 mg once daily (≥60 kg) or 5 mg once daily (&lt;60 kg) beginning 24 hours after the last dose of clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-20846599','lexi-content-ref-18569863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-20846599','lexi-content-ref-18569863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Transitioning from ticagrelor:</i> Give prasugrel 60 mg loading dose 12 to 24 hours after the last dose of ticagrelor, followed the next day by 10 mg once daily (≥60 kg) or 5 mg once daily (&lt;60 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24333493','lexi-content-ref-20846599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24333493','lexi-content-ref-20846599'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990266"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary; use caution in moderate to severe impairment (patients are generally at higher risk of bleeding).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987457"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment (Child-Pugh class A and B): No dosage adjustment necessary for mild-to-moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution (patients are generally at higher risk of bleeding).</p></div>
<div class="block doe drugH1Div" id="F7910728"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Patients ≥75 years of age: Use is generally not recommended; may be considered in high-risk situations (eg, patients with diabetes or history of myocardial infarction).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome (non-ST-elevation myocardial infarction, unstable angina, or ST-elevation myocardial infarction) managed by percutaneous coronary intervention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Patients ≥75 years of age:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i> See adult dosing</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose: </i>
<b>Oral: </b>5 mg once daily in combination with aspirin beginning the day after PCI. An alternative P2Y<sub>12</sub> inhibitor may be considered if bleeding is a major concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-32687741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-32687741'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F7910605"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (8%), hypotension (4%), atrial fibrillation (3%), bradycardia (3%), peripheral edema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (6%), dizziness (4%), fatigue (4%), noncardiac chest pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (≤7%), hyperlipidemia (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (5%), diarrhea (2%), gastrointestinal hemorrhage (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (3%), anemia (2%), major hemorrhage (2%), minor hemorrhage (2%), major hemorrhage (life-threatening: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (5%), limb pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (6%), dyspnea (5%), cough (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylaxis, angioedema, hematoma, hemoptysis, hemorrhage (requiring inotropes or transfusion), hypersensitivity reaction, intracranial hemorrhage (symptomatic), re-operation due to bleeding, thrombocytopenia, thrombotic thrombocytopenic purpura</p></div>
<div class="block coi drugH1Div" id="F7910301"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis) to prasugrel or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage); prior transient ischemic attack or stroke.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Severe hepatic impairment (Child-Pugh Class C).</p></div>
<div class="block war drugH1Div" id="F7910302"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: <b>[US Boxed Warning]: May cause significant, sometimes fatal, bleeding. Do not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. Additional risk factors for bleeding include body weight &lt;60 kg, propensity to bleed (eg, recent trauma, recent surgery, recent or recurrent GI bleeding, active peptic ulcer disease, severe hepatic impairment, or moderate to severe renal impairment), and concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, long-term use of NSAIDs). Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, PCI, CABG, or other surgical procedures in the setting of prasugrel. If possible, manage bleeding without discontinuing prasugrel. Discontinuing prasugrel, particularly in the first few weeks after ACS, increases the risk of subsequent cardiovascular events. </b>Management of bleeding episodes includes the use of PRBCs and platelet transfusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity, including angioedema, has been reported, including in patients with a previous history of thienopyridine hypersensitivity. Because of structural similarities, cross-reactivity is possible among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with previous history of thienopyridine hypersensitivity. Use of prasugrel is contraindicated in patients with hypersensitivity (eg, anaphylaxis) to prasugrel.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic thrombocytopenic purpura (TTP): Cases of TTP (usually occurring within the first 2 weeks of therapy), resulting in some fatalities, have been reported with prasugrel; urgent plasmapheresis is required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with recent or recurrent GI bleeding or active peptic ulcer disease (patients are generally at higher risk of bleeding).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment (patients are generally at higher risk of bleeding).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate to severe renal impairment (patients are generally at higher risk of bleeding).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: <b>[US Boxed Warning]: In patients ≥75 years, use is generally not recommended due to increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of MI) in which its effect appears to be greater and its use may be considered.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. In patients receiving dual antiplatelet therapy (aspirin plus P2Y<sub>12</sub> receptor blocker [eg, clopidogrel, prasugrel, ticagrelor, ticlopidine]) or thienopyridine monotherapy, the thienopyridine should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk (aspirin should <i>not</i> be discontinued); however, dual antiplatelet therapy should <i>not</i> be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Low-weight patients: In patients weighing &lt;60 kg, risk of bleeding increased; consider lower maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: <b>[US Boxed Warning]: Do not initiate therapy in patients likely to undergo urgent CABG surgery; when possible, discontinue ≥7 days prior to any surgery; increased risk of bleeding.</b> Patient-specific situations should be discussed with a cardiologist, interventional cardiologist, and a cardiac surgeon (ACC/AHA [Grines 2007]; ACC/AHA [Hillis 2011]; ACC/AHA [Lawton 2022]). In patients undergoing noncardiac surgery, the risks and benefits of prasugrel should be evaluated between the surgeon and the cardiology team. Elective noncardiac surgery should not be performed in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively within 30 days following bare metal stent placement or within 3 months of drug-eluting stent placement. In patients undergoing urgent noncardiac surgery during the first 4 to 6 weeks after BMS or DES placement, continue DAPT. In patients undergoing noncardiac surgery that requires discontinuation of prasugrel, hold for 7 days preoperatively, continue aspirin and restart prasugrel as soon as possible (eg, ≤24 hours) after surgery based on bleeding and thrombotic risks (ACC/AHA [Fleisher 2014]; ACC/AHA [Lawton 2022]; ACC/AHA [Levine 2016]; ACCP [Douketis 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: For patients who undergo percutaneous coronary intervention with stenting, premature interruption of therapy may result in increased risk of myocardial infarction, stent thrombosis, stroke, or death. If therapy must be held temporarily (eg, bleeding, surgery), restart as soon as possible unless the reason for discontinuation is a stroke or TIA where subsequent use is contraindicated. Duration of therapy is determined by the type of stent placed (bare metal or drug eluting), whether an acute coronary syndrome event was ongoing at the time of placement, as well as risks for bleeding and thrombosis (ACC/AHA [Lawton 2022]).</p></div>
<div class="block foc drugH1Div" id="F7910736"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effient: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F7910292"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322568"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Effient Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $22.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $22.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Prasugrel HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $16.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $16.50 - $16.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870780"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effient: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block adm drugH1Div" id="F7910732"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals. In an emergent primary PCI setting, crushing the tablets (using a commercially available syringe crusher) and mixing with 25 mL of water led to faster absorption and a quicker, more potent antiplatelet effect seen as early as 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27012781','lexi-content-ref-34167672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27012781','lexi-content-ref-34167672'])">Ref</a></span>). In addition, according to the manufacturer, tablets may be chewed and swallowed (bitter to taste) or crushed and mixed in food or liquid (eg, applesauce, juice, water) and immediately administered by mouth or gastric tube. Administration via an enteral tube that bypasses the acidic environment of the stomach may result in reduced bioavailability of prasugrel (data on file, Daiichi Sankyo-Lilly 2012).</p></div>
<div class="block meg drugH1Div" id="F7984963"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022307s018lbl.pdf%23page%3D21&amp;token=Xdn1KpHVSLrgR0u9CWBjNT6KJtpgyYag0bSKdo4V1VCMoRL5O6BJt2X%2F16t4ChN9aOPKrmysAWSm%2Fw%2BOljQ32g%2FBJqo02dJ4RF%2Fl73Wpb2qu28mFNZ0I9ijk5Agoq69U&amp;TOPIC_ID=9533" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022307s018lbl.pdf#page=21</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F7910296"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Acute coronary syndrome managed by percutaneous coronary intervention:</b> To reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention for unstable angina, non-ST-elevation myocardial infarction (MI), or ST-elevation MI.</p></div>
<div class="block mst drugH1Div" id="F10227670"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Prasugrel may be confused with pravastatin, propranolol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Prasugrel is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution, especially in patients 75 years and older due to increased risk of bleeding compared with clopidogrel; however, cardiovascular benefit in certain older adults may offset risk. Consider a lower dose (5 mg/day) if used in patients 75 years and older (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299935"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8018470"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib.  Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cangrelor: May diminish the antiplatelet effect of Prasugrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Prasugrel, Cangrelor is expected to decrease binding of Prasugrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. Management: Avoid administration of prasugrel until cangrelor is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Diamorphine may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telotristat Ethyl: May decrease serum concentrations of the active metabolite(s) of Prasugrel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F7910298"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. Information related to use during pregnancy is limited (Tello-Montoliu 2013).</p></div>
<div class="block brc drugH1Div" id="F20311220"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if prasugrel is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F7910734"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hemoglobin and hematocrit periodically.</p></div>
<div class="block pha drugH1Div" id="F7910614"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Prasugrel, an inhibitor of platelet activation and aggregation, is a prodrug that is metabolized to both active (R-138727) and inactive metabolites. The active metabolite irreversibly blocks the P2Y<sub>12</sub> component of ADP receptors on the platelet, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet activation and aggregation</p></div>
<div class="block phk drugH1Div" id="F7910616"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Inhibition of platelet aggregation (IPA): Dose dependent: 60 mg loading dose: &lt;30 minutes; median time to reach ≥20% IPA: 30 minutes (Brandt 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Time to maximal IPA: Dose-dependent: <b>Note:</b> Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry: 60 mg loading dose: Occurs ~4 hours post administration; Mean IPA (ADP 5 micromole/L): ~84.1%; Mean IPA (ADP 20 micromole/L): ~78.8% (Brandt 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of effect: Platelet aggregation gradually returns to baseline values over 5 to 9 days after discontinuation; reflective of new platelet production.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; ≥79%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Active metabolite: V<sub>d</sub>: 44 to 68 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Active metabolite: ~98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapid intestinal and serum metabolism via esterase-mediated hydrolysis to a thiolactone intermediate (inactive), which is then converted, via CYP450-mediated (primarily CYP3A4 and CYP2B6) oxidation, to an active metabolite (R-138727) (Farid 2007; Riley 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Active metabolite: ~7 hours (range 2 to 15 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Active metabolite: ~30 minutes; With high-fat/high-calorie meal: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~68% inactive metabolites); feces (27% inactive metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51219799"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with ESRD, both C<sub>max</sub> and AUC<sub>0-t last</sub> of the active metabolite were approximately half that in healthy patients and in patients with moderate renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The AUC of active metabolite was 19% higher in patients 75 years and older than in patients younger than 75 years.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: The AUC of active metabolite was approximately 19% higher in Chinese, Japanese, and Korean subjects than in white subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: The AUC of the active metabolite is approximately 30% to 40% higher in subjects with a body weight of less than 60 kg compared to those weighing 60 kg or more.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962010"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Effient | Fluidin | Nefagrel | Trocal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel aristo | Prasugrel hcs | Prasugrel ratiopharm | Prasugrel sandoz | Prasulan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Effient | Prasugrel SCP</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Apagrel | Appras | Asurel | Efigrel | Efirel | Hemagrel | Opagrel | Prapid | Prasulet | Prasurel | Prasuva</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Efient</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bewim | Efient | Fluidoro | Prasugrel teva | Tosynal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel mepha</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Effient | Perkunal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Efient | Eliskardia</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasillt | Prasugrel accord | Prasugrel AL | Prasugrel aristo | Prasugrel beta | Prasugrel biomo | Prasugrel Glenmark | Prasugrel heumann | Prasugrel ratiopharm | Prasugrelhydrobromid Zentiva | Prasuhexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Prasusafe | Sugrel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Perkunal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Efient</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel combix | Prasugrel krka | Prasugrel qualigen | Prasugrel ratiopharm | Prasugrel stada | Prasugrel teva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Efient</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel arrow | Prasugrel biogaran | Prasugrel cristers | Prasugrel eg | Prasugrel krka | Prasugrel mylan | Prasugrel teva | Prasugrel zentiva lab</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel vocate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bewim | Efient | Eliskardia</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel accord | Prasugrel krka | Prasugrel mylan | Prasugrel rowex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Apagrel | Aplet | Effient | Efiplat | Pangrel | Pasugen | Prasact | Prasita | Prasudin | Prasudoc | Prasugrin | Prasulet | Prasumax | Prasurel | Prasusafe | Prasutab | Prasuten | Prasuvas | Prasuvix | Prax | Prethromb | Redigrel | Troyplatt</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel mylan | Prasugrel teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Effient | Lexar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Pragrel | Prasu | Prasusafe</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lexar</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Efient | Eliskardia</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Efient</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Efient | Eliskardia</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel | Prasugrel mylan | Prasugrel teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel krka</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Effient | Prasugrel</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atcogrel | Bestegrel | Effin | Persiva | Prag | Pragi | Prasubar | Prasug | Prasulet | Prasumac | Prezent | Prisa | Samig | Superplat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bewim | Efient</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Prasugrel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Agreplac</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Efient</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Antagrex | Effient</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Efient | Prasugrel ebb | Prasugrel krka | Prasugrel mylan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Efient | Eliskardia | Prasugrel | Tosynal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bewim | Efient | Sigrada</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Effient</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Efient</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Sagrada</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Prasusafe</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Glitax | Perkunal | Sugrel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Effient | Perkunal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Razugrel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Efient</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23630129">
<a name="23630129"></a>Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi:10.1161/CIR.0b013e31828478ac<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23630129/pubmed" id="23630129" target="_blank">23630129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24333493">
<a name="24333493"></a>Angiolillo DJ, Curzen N, Gurbel P, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (switching anti platelet-2). <i>J Am Coll Cardiol.</i> 2014;63(15):1500-1509. doi:10.1016/j.jacc.2013.11.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/24333493/pubmed" id="24333493" target="_blank">24333493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084738">
<a name="29084738"></a>Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. <i>Circulation</i>. 2017;136(20):1955-1975. doi:10.1161/CIRCULATIONAHA.117.031164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/29084738/pubmed" id="29084738" target="_blank">29084738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20846599">
<a name="20846599"></a>Angiolillo DJ, Saucedo JF, Deraad R, et al; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (Switching Anti Platelet) study. <i>J Am Coll Cardiol</i>. 2010;56(13):1017-1023. doi:10.1016/j.jacc.2010.02.072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/20846599/pubmed" id="20846599" target="_blank">20846599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17174640">
<a name="17174640"></a>Brandt JT, Payne CD, Wiviott SD, et al, “A Comparison of Prasugrel and Clopidogrel Loading Doses on Platelet Function: Magnitude of Platelet Inhibition is Related to Active Metabolite Formation,” <i>Am Heart J</i>, 2007, 153(1):66.e9-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17174640/pubmed" id="17174640" target="_blank">17174640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.2021">
<a name="Cutlip.2021"></a>Cutlip D, Lincoff AM. Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Effient.1">
<a name="Effient.1"></a>Effient (prasugrel) [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23083774">
<a name="23083774"></a>Erlinge D, Ten Berg J, Foley D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. <i>J Am Coll Cardiol</i>. 2012;60(20):2032-2040. doi:10.1016/j.jacc.2012.08.964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23083774/pubmed" id="23083774" target="_blank">23083774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17403916">
<a name="17403916"></a>Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. <i>Drug Metab Dispos</i>. 2007; 35(5):1096-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17403916/pubmed" id="17403916" target="_blank">17403916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17224480">
<a name="17224480"></a>Grines CL, Bonow RO, Casey DE, et al. AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association with representation from The American College Of Physicians. <i>Circulation.</i> 2007;115(6):813-818. Available at http://www.acc.org/qualityandscience/clinical/pdfs/Final_Dual_Antiplatelet_Statement_010507.pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17224480/pubmed" id="17224480" target="_blank">17224480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JAMP.1">
<a name="JAMP.1"></a>JAMP Prasugrel (prasugrel) [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32882163">
<a name="32882163"></a>Kim HS, Kang J, Hwang D, et al; HOST-REDUCE-POLYTECH-ACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2020;396(10257):1079-1089. doi:10.1016/S0140-6736(20)31791-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/32882163/pubmed" id="32882163" target="_blank">32882163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J<i> Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27036918">
<a name="27036918"></a>Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2016;68(10):1082-1115. doi:10.1016/j.jacc.2016.03.513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/27036918/pubmed" id="27036918" target="_blank">27036918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” <i>Circulation</i>, 2011, 124(23):e574-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25154978">
<a name="25154978"></a>Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Nat Rev Cardiol</i>. 2014;11(10):597-606. doi:10.1038/nrcardio.2014.104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25154978/pubmed" id="25154978" target="_blank">25154978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399658">
<a name="25399658"></a>Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>N Engl J Med</i>. 2014;371(23):2155-2166. doi:10.1056/NEJMoa1409312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/25399658/pubmed" id="25399658" target="_blank">25399658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32687741">
<a name="32687741"></a>Menichelli M, Neumann FJ, Ndrepepa G, et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results from a randomized trial. <i>Ann Intern Med</i>. 2020;173(6):436-444. doi:10.7326/M20-1806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/32687741/pubmed" id="32687741" target="_blank">32687741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23991622">
<a name="23991622"></a>Montalescot G, Bolognese L, Dudek D, et al; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. <i>N Engl J Med.</i> 2013;369(11):999-1010. doi:10.1056/NEJMoa1308075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23991622/pubmed" id="23991622" target="_blank">23991622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32551860">
<a name="32551860"></a>O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y<sub>12</sub> inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Circulation</i>. 2020;142(6):538-545. doi:10.1161/CIRCULATIONAHA.120.046251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/32551860/pubmed" id="32551860" target="_blank">32551860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18569863">
<a name="18569863"></a>Payne CD, Li YG, Brandt JT, et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aggregation in aspirin-treated subjects. <i>Platelets.</i> 2008;19(4):275-281. doi:10.1080/09537100801891640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/18569863/pubmed" id="18569863" target="_blank">18569863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628601">
<a name="21628601"></a>Riesmeyer JS, Salazar DE, Weerakkody GJ, et al, "Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy," <i>J Clin Pharmacol</i>, 2012, 52(6):789-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/21628601/pubmed" id="21628601" target="_blank">21628601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18499874">
<a name="18499874"></a>Riley AB, Tafreshi MJ, Haber SL. Prasugrel: a novel antiplatelet agent. <i>Am J Health Syst Pharm</i>. 2008;65(11):1019-1028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/18499874/pubmed" id="18499874" target="_blank">18499874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22920930">
<a name="22920930"></a>Roe MT, Armstrong PW, Fox KA, et al, “Prasugrel versus Clopidogrel for Acute Coronary Syndromes Without Revascularization,” <i>N Engl J Med</i>, 2012, 367(14):1297-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/22920930/pubmed" id="22920930" target="_blank">22920930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012781">
<a name="27012781"></a>Rollini F, Franchi F, Hu J, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: The CRUSH study. <i>J Am Coll Cardiol</i>. 2016;67(17):1994-2004. doi:10.1016/j.jacc.2016.02.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/27012781/pubmed" id="27012781" target="_blank">27012781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19888568">
<a name="19888568"></a>Small DS, Kothare P, Yuen E, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. <i>Eur J Clin Pharmacol</i>. 2010;66(2):127-135. doi:10.1007/s00228-009-0737-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/19888568/pubmed" id="19888568" target="_blank">19888568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26925883">
<a name="26925883"></a>Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi:10.1038/ajg.2016.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/26925883/pubmed" id="26925883" target="_blank">26925883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23143651">
<a name="23143651"></a>Tello-Montoliu A, Seecheran NA, Angiolillo DJ. Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice. <i>J Thromb Thrombolysis.</i> 2013;36(3):348-351. doi:10.1007/s11239-012-0830-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/23143651/pubmed" id="23143651" target="_blank">23143651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34167672">
<a name="34167672"></a>Vogel RF, Delewi R, Angiolillo DJ, et al. Pharmacodynamic effects of pre-hospital administered crushed prasugrel in patients with ST-segment elevation myocardial infarction. <i>JACC Cardiovasc Interv</i>. 2021;14(12):1323-1333. doi:10.1016/j.jcin.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/34167672/pubmed" id="34167672" target="_blank">34167672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982182">
<a name="17982182"></a>Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2007;357(20):2001-2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prasugrel-drug-information/abstract-text/17982182/pubmed" id="17982182" target="_blank">17982182</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9533 Version 315.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
